# Pulmonx Corp: overview LUNG · Nasdaq · CIK 1127537 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lung.md) · [Financials](/companies/lung/financials.md) · [Filings](/companies/lung/filings.md) · [Insiders](/companies/lung/insiders.md) Latest reported revenue: [$22.8m](/filings/0001127537-26-000039.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001127537-26-000039). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [20.4](/filings/0001127537-25-000059.md) | [23.8 d](/filings/0001127537-26-000015.md) | [22.5](/filings/0001127537-26-000025.md) | [23.9](/filings/0001127537-26-000039.md) | [21.5](/filings/0001127537-25-000059.md) | [22.6 d](/filings/0001127537-26-000015.md) | [20.6](/filings/0001127537-26-000025.md) | [22.8](/filings/0001127537-26-000039.md) | | Gross margin | % | [73.7%](/filings/0001127537-25-000059.md) | [74.0% d](/filings/0001127537-26-000015.md) | [72.5%](/filings/0001127537-26-000025.md) | [72.1%](/filings/0001127537-26-000039.md) | [74.7%](/filings/0001127537-25-000059.md) | [77.6% d](/filings/0001127537-26-000015.md) | [77.9%](/filings/0001127537-26-000025.md) | [78.0%](/filings/0001127537-26-000039.md) | | Operating margin | % | [(69.3%)](/filings/0001127537-25-000059.md) | [(56.5%) d](/filings/0001127537-26-000015.md) | [(64.6%)](/filings/0001127537-26-000025.md) | [(62.0%)](/filings/0001127537-26-000039.md) | [(66.9%)](/filings/0001127537-25-000059.md) | [(43.8%) d](/filings/0001127537-26-000015.md) | [(62.9%)](/filings/0001127537-26-000025.md) | [(39.8%)](/filings/0001127537-26-000039.md) | | Net margin | % | [(69.4%)](/filings/0001127537-25-000059.md) | [(55.4%) d](/filings/0001127537-26-000015.md) | [(64.1%)](/filings/0001127537-26-000039.md) | [(63.6%)](/filings/0001127537-26-000039.md) | [(64.9%)](/filings/0001127537-25-000059.md) | [(46.1%) d](/filings/0001127537-26-000015.md) | [(66.3%)](/filings/0001127537-26-000039.md) | [(44.3%)](/filings/0001127537-26-000039.md) | | Diluted EPS | $ per share | [(0.36)](/filings/0001127537-25-000059.md) | not reported | [(0.36)](/filings/0001127537-26-000025.md) | [(0.38)](/filings/0001127537-26-000039.md) | [(0.34)](/filings/0001127537-25-000059.md) | not reported | [(0.33)](/filings/0001127537-26-000025.md) | [(0.24)](/filings/0001127537-26-000039.md) | | Free cash flow | $m | [(7.7) d](/filings/0001127537-25-000059.md) | [(6.8) d](/filings/0001127537-26-000015.md) | [(13.5)](/filings/0001127537-26-000025.md) | [(4.0) d](/filings/0001127537-26-000039.md) | [(8.3) d](/filings/0001127537-25-000059.md) | [(7.1) d](/filings/0001127537-26-000015.md) | [(10.1)](/filings/0001127537-26-000025.md) | [(5.2) d](/filings/0001127537-26-000039.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [48.4](/filings/0001127537-23-000011.md) | [53.7](/filings/0001127537-24-000024.md) | [68.7](/filings/0001127537-25-000012.md) | [83.8](/filings/0001127537-26-000015.md) | [90.5](/filings/0001127537-26-000015.md) | | Gross margin | % | [73.6%](/filings/0001127537-23-000011.md) | [74.3%](/filings/0001127537-24-000024.md) | [73.9%](/filings/0001127537-25-000012.md) | [74.0%](/filings/0001127537-26-000015.md) | [74.2%](/filings/0001127537-26-000015.md) | | Operating margin | % | [(97.7%)](/filings/0001127537-23-000011.md) | [(109.3%)](/filings/0001127537-24-000024.md) | [(90.2%)](/filings/0001127537-25-000012.md) | [(68.9%)](/filings/0001127537-26-000015.md) | [(59.3%)](/filings/0001127537-26-000015.md) | | Net margin | % | [(100.5%)](/filings/0001127537-23-000011.md) | [(109.8%)](/filings/0001127537-24-000024.md) | [(88.6%)](/filings/0001127537-25-000012.md) | [(67.3%)](/filings/0001127537-26-000015.md) | [(59.7%)](/filings/0001127537-26-000015.md) | | Diluted EPS | $ per share | [(1.35)](/filings/0001127537-23-000011.md) | [(1.59)](/filings/0001127537-24-000024.md) | [(1.60)](/filings/0001127537-25-000012.md) | [(1.44)](/filings/0001127537-26-000015.md) | [(1.33)](/filings/0001127537-26-000015.md) | | Free cash flow | $m | [(45.1)](/filings/0001127537-23-000011.md) | [(46.4)](/filings/0001127537-24-000024.md) | [(38.4)](/filings/0001127537-25-000012.md) | [(33.0)](/filings/0001127537-26-000015.md) | [(32.8)](/filings/0001127537-26-000015.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lung/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2021-07-13 | [Boston Scientific Corp](/insiders/885725.md) | 10% owner | Sale (S) | 2,500,000 | $37.45 | $93.6m | [Form 4](/filings/0001225208-21-010646.md) | | 2021-04-06 | [Boston Scientific Corp](/insiders/885725.md) | 10% owner | Sale (S) | 650,000 | $43.60 | $28.3m | [Form 4](/filings/0001225208-21-006650.md) | | 2021-03-30 | [Boston Scientific Corp](/insiders/885725.md) | 10% owner | Sale (S) | 1,350,000 | $40.80 | $55.1m | [Form 4](/filings/0001225208-21-006217.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $6.0m | 4,612,331 | | Reduced −112,660 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $3.8m | 2,922,921 | | Reduced −1,070,641 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $3.6m | 2,788,323 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.1m | 1,630,219 | | Reduced −4,045 | | [ExodusPoint Capital Management, LP](/funds/1736225.md) | 2026-06-30 | $1.6m | 1,223,555 | | Reduced −720,279 | | [Almitas Capital LLC](/funds/1596468.md) | 2026-06-30 | $1.4m | 1,064,202 | | New +1,064,202 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.1m | 882,490 | | Reduced −1,779,117 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $1.1m | 815,436 | | Added +47,148 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $985.7k | 758,231 | | Added +624,961 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $978.3k | 752,541 | | Unchanged | ## Recent filings [All 430 filings](/companies/lung/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 16:07 ET | [8-K](/filings/0001127537-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001127537-26-000042 | | 2026-08-04 | 16:46 ET | [10-Q](/filings/0001127537-26-000039.md) | Quarterly report, period 2026-06-30 | 0001127537-26-000039 | | 2026-07-29 | 16:07 ET | [8-K](/filings/0001127537-26-000035.md) | 2.02 Results of operations | 0001127537-26-000035 | | 2026-06-04 | 16:04 ET | [8-K](/filings/0001127537-26-000031.md) | 5.07 Shareholder vote results | 0001127537-26-000031 | | 2026-05-04 | 16:32 ET | [10-Q](/filings/0001127537-26-000025.md) | Quarterly report, period 2026-03-31 | 0001127537-26-000025 | | 2026-04-29 | 16:13 ET | [8-K](/filings/0001127537-26-000020.md) | 2.02 Results of operations | 0001127537-26-000020 | | 2026-04-22 | 16:07 ET | [DEF 14A](/filings/0001140361-26-016105.md) | Proxy statement, period 2026-06-04 | 0001140361-26-016105 | | 2026-03-10 | 17:03 ET | [10-K](/filings/0001127537-26-000015.md) | Annual report, period 2025-12-31 | 0001127537-26-000015 | | 2026-03-05 | 19:10 ET | [8-K](/filings/0001193125-26-092064.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-092064 | | 2026-03-04 | 16:11 ET | [8-K](/filings/0001127537-26-000003.md) | 2.02 Results of operations | 0001127537-26-000003 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001127537-26-000015.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/36744eb0-1185-4de6-8af6-6d8555ca542b) ## About the filer - CIK: 1127537 - Tickers: LUNG - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:08 ET. No prices; not investment advice.